# Optimal Remifentanil Ce for Preventing Severe Cough and Hyperdynamic Response During Tracheal Extubation

Study · id `cardio:ct-nct03132519` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03132519](<https://clinicaltrials.gov/study/NCT03132519>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03132519

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 364 participants.

## Technical summary

Registry record NCT03132519. Randomized; quadruple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2015-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 364 participants (enrolled count; ClinicalTrials.gov record NCT03132519, source copy `cardio:ctgov-nct03132519-2017-05-02`, retrieved 2026-10-26)
- Start date: 2013-10 (registry gives no type) (ClinicalTrials.gov record NCT03132519, source copy `cardio:ctgov-nct03132519-2017-05-02`, retrieved 2026-10-26)
- Primary completion: 2015-11 (actual) (ClinicalTrials.gov record NCT03132519, source copy `cardio:ctgov-nct03132519-2017-05-02`, retrieved 2026-10-26)
- Completion: 2016-02 (actual) (ClinicalTrials.gov record NCT03132519, source copy `cardio:ctgov-nct03132519-2017-05-02`, retrieved 2026-10-26)
- Countries: Colombia (ClinicalTrials.gov record NCT03132519, source copy `cardio:ctgov-nct03132519-2017-05-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03132519-2017-05-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Optimal Remifentanil Ce for Preventing Severe Cough and Hyperdynamic Response During Tracheal Extubation
- Acronym: REX
- Condition: Cough
- Condition: Hypertension
- Intervention (Drug): Remifentanil
- Lead sponsor: Fundacion Clinica Valle del Lili
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: b010d7ad3eb3c15e9de2ec3fd484874810db216871a1d5693863e8a8de354a20
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
